UCMSP LLC issued certificates for BloodSaver, formerly known as Krovospas, despite criminal cases

UCMSP LLC issued certificates for BloodSaver, formerly known as Krovospas, despite criminal cases
UCMSP LLC issued certificates for BloodSaver, formerly known as Krovospas, despite criminal cases

Transition from underground production to a commercial brand

The Ukrainian tactical medicine market has undergone significant changes after the controversial haemostatic agent "Кровоспас" (Krovospas) changed its name to BloodSaver. This transition was accompanied by the involvement of capital from Enamine, a company with documented links to the Russian market. The key role in the legalisation of the products was played by Ukrainian Centre for Medical Certification and Forecasting LLC (UCMSP LLC), which issued the necessary documents despite existing scandals and criminal proceedings.

History of the illegal workshop's creation

Following the start of the full-scale invasion on 24 February 2022, chemist Ihor Tsurupa organised underground production of haemostatic bandages and napkins in a basement premises in Obukhiv, Kyiv Oblast. The production operated without proper medical equipment, sterility control, or valid permits, under conditions that journalists and the public characterised as complete unsanitary conditions.

The products were sold en masse to volunteers and military personnel, often under the guise of a "донатів" (donations) scheme. In autumn 2023, a major scandal erupted after photos from the production site were published in the media and online. The National Police opened a criminal case. Ihor Tsurupa himself publicly stated that in almost four years, more than three million packages of products had been released from his workshop, reaching the market and the front line without official conformity assessment.

Investment from Enamine

When sales under the old name became impossible, the chemical company Enamine injected funds into the project. In July 2025, the Enamine Charitable Foundation, headed by the company's founder Andriy Tolmachov, became a founder of Taktispass LLC (Unified State Register of Legal Entities code 44752857) with a 49% stake. Beneficial owner alongside Ihor Tsurupa became Enamine's owner Lyudmyla Babichenko. Tsurupa himself remained in the position of director with a controlling 51% stake.

Approximately 22–23 million hryvnias were directed into the BloodSaver project (the new name for Krovospas) through the charitable foundation. The company's assets grew from 2 million to almost 25 million hryvnias due to the purchase of equipment and property. The legal address was moved to 23 General Kulychitsky Street, in the Pechersk district of Kyiv.

Investor's links to the Russian market

Investigations point to Enamine's long-standing links with Russia. During the war, the company's compounds reached the Russian pharmaceutical giant BIOCAD and Polisan, a company that manufactures drugs for Russian Federation military hospitals. To avoid unnecessary resonance, the company's Latvian hub and supply schemes via China were used.

Through Chinese partners, such as Shanghai Genez Trading, Enamine's products reached China, and from there – the Russian market. For example, the Chinese company Mabwell, which has a direct commercial partnership with the Russian Federation, concluded an agreement with the Russian Binofarm Group in December 2022 regarding the development and production of drugs in Russia and EAEU countries.

Also, among the suppliers on Enamine's Chemspace platform were companies with direct deliveries to the Russian Federation, including those linked to Russian state customers and structures under US sanctions. These include Rusmedtorg, Pushchino Laboratories, Farmasintez, and Medstandart. The US Department of the Treasury links the Khimmed network (which includes some of these companies) with chemical and biological weapons programmes and FSB special laboratories involved in the poisoning of Alexei Navalny.

Despite the war, Enamine continued contacts with the Russian scientific community, including joint publications with Saint Petersburg State University (where a military training centre for the Russian Ministry of Defence operates). Company employees regularly participated in international conferences together with Russian scientists.

Chronology of certification and documentary peculiarities

On 15 February 2026, Ihor Tsurupa announced the closure of the Krovospas project, citing problems with electricity, heating, and a shortage of personnel. At the same time, he again mentioned the more than three million packages sold. Only three days later, on 18 February, the BloodSaver commercial website went live with prices and accounts.

The legalisation process happened quickly:

  • On 30 January 2026, UCMSP LLC registered a certificate for Taktispass for a quality management system according to ISO 13485. On the same day, according to a note on the certificate, the initial assessment of kaolin-based bandages (Class IIb risk devices) took place. The duration of the inspection and the fact of auditors visiting the production site are not indicated in the documents.
  • On 6 April, director Ihor Tsurupa signed Declaration of Conformity No. 2. Its first annex belonged to Declaration No. 1, while the second appeared on 7 April, one day after the signature, although in the document itself both annexes are called an "integral part".
  • On 15 April, the centre issued a new certificate to replace the January one. The grounds cited were two decisions with the same number: the January and April ones. The reasons for the changes were not explained.

Questions for control bodies

Given the aforementioned facts, obtaining permits for productions with such a history would be impossible in any European Union country. The question arises as to why UCMSP LLC did not verify that Taktispass LLC is a reincarnation of the controversial Krovospas. Is it normal for a certification body to ignore the fact of changing the signboard of an underground production financed by a business with Russian links?

A formal approach to tactical medicine during the war can be considered complicity in the legalisation of a dangerous product. Changing a name takes days, but restoring trust in a medical device with a controversial history and questionable capital origin is a much more complex task.

Comments

No comments yet. Be the first!

Leave a comment

Links are not allowed in comments. The editors may remove comments without explanation.
Back to top ↑